Concepedia

Fumitoshi Asai

FA

46

Publications

1.8K

Citations

20

H-Index

1982

Active since

Affiliations

Azabu University(Current)

Daiichi-Sankyo (Japan)

The University of Osaka

Okayama University

Eli Lilly (United States)

Fumitoshi Asai is an author at Azabu University specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1982–2020

46

Publications

46

The <i>in vivo</i> pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

Atsuhiro Sugidachi, Fumitoshi Asai, Taketoshi Ogawa et al. · British Journal of Pharmacology · 2000 · 235 citations · Full text

The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite

Atsuhiro Sugidachi, Taketoshi Ogawa, Atsushi Kurihara et al. · Journal of Thrombosis and Haemostasis · 2007 · 218 citations · Full text

, , +8

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y<sub>12</sub> inhibitor, compared with clopidogrel in healthy humans

Joseph A. Jakubowski, Nobuko Matsushima, Fumitoshi Asai et al. · British Journal of Clinical Pharmacology · 2006 · 128 citations · Full text

Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type G<sub>i</sub>‐linked P2T antagonist, CS‐747

Atsuhiro Sugidachi, Fumitoshi Asai, Kenji Yoneda et al. · British Journal of Pharmacology · 2001 · 110 citations · Full text

, , +18

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y<sub>12</sub> inhibitor: A single ascending dose study in healthy humans

Fumitoshi Asai, Joseph A. Jakubowski, Hideo Naganuma et al. · Platelets · 2006 · 108 citations

Rows per page

1–5 of 46